S100A8 and COVID-19: Paquinimod treatment could reduce these neutrophils and regain anti-viral responses, unveiling key roles of S100A8/A9 and aberrant neutrophils in the pathogenesis of COVID-19 and highlighting new opportunities for therapeutic intervention (69).